Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

• Published in: Blood Vol. 138; no. Supplement 1; p. 1655
• Main Authors: Perrot, Aurore, Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar J., Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O'Dwyer, Michael E., Venner, Chris P., Weisel, Katja, Mace, Joseph R., Raje, Noopur S., Tiab, Mourad, Macro, Magaret, Frenzel, Laurent, Leleu, Xavier, Liu, Kevin, Fastenau, John, Gries, Katharine S., Ho, Kai Fai, Mistry, Pankaj, Tromp, Brenda, Delioukina, Maria, Vermeulen, Jessica, Usmani, Saad Z.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 23.11.2021

Introduction: Multiple myeloma (MM) is a chronic hematologic malignancy with a high symptom burden that can have a substantial negative impact on patients' (pts) health-related quality of life (HRQoL). The introduction of novel triplet regimens for newly diagnosed MM (NDMM) has extended progres...